CSL (OTCMKTS:CSLLY) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of CSL (OTCMKTS:CSLLY) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

CSL Price Performance

OTCMKTS CSLLY opened at $86.16 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18. CSL has a twelve month low of $83.31 and a twelve month high of $109.00. The stock has a fifty day simple moving average of $89.07 and a 200 day simple moving average of $96.47.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.